BR0108193A - Processo para tratamento ou inibição de dano celular ou morte celular - Google Patents

Processo para tratamento ou inibição de dano celular ou morte celular

Info

Publication number
BR0108193A
BR0108193A BR0108193-4A BR0108193A BR0108193A BR 0108193 A BR0108193 A BR 0108193A BR 0108193 A BR0108193 A BR 0108193A BR 0108193 A BR0108193 A BR 0108193A
Authority
BR
Brazil
Prior art keywords
treating
cell
damage
inhibiting
cell death
Prior art date
Application number
BR0108193-4A
Other languages
English (en)
Inventor
Gregory Scott Friedrichs
Robert Edward Swillo
Brian Hong-N Jow
Terry Roy Bridal
Randal Edward Numann
Linda Marie Warner
Loran Marie Killar
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BR0108193A publication Critical patent/BR0108193A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"PROCESSO PARA TRATAMENTO OU INIBIçãO DE DANO CELULAR OU MORTE CELULAR". A presente invenção fornece um processo para o tratamento ou a inibição de dano celular ou morte celular após um evento isquêmico, para o tratamento ou a inibição de dano por reperfusão e para a redução de mortalidade após um infarto de miocárdio fornecendo terapia com um antagonista à TNF<244>.
BR0108193-4A 2000-02-10 2001-02-08 Processo para tratamento ou inibição de dano celular ou morte celular BR0108193A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50186200A 2000-02-10 2000-02-10
PCT/US2001/004048 WO2001058473A1 (en) 2000-02-10 2001-02-08 Method of treating or inhibiting cellular injury or cell death

Publications (1)

Publication Number Publication Date
BR0108193A true BR0108193A (pt) 2003-02-25

Family

ID=23995312

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0108193-4A BR0108193A (pt) 2000-02-10 2001-02-08 Processo para tratamento ou inibição de dano celular ou morte celular

Country Status (9)

Country Link
EP (1) EP1261364A1 (pt)
JP (1) JP2003522155A (pt)
CN (1) CN1406132A (pt)
AR (1) AR033965A1 (pt)
AU (1) AU2001236764A1 (pt)
BR (1) BR0108193A (pt)
CA (1) CA2399436A1 (pt)
MX (1) MXPA02007683A (pt)
WO (1) WO2001058473A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1478394T1 (sl) 2002-02-27 2008-12-31 Immunex Corp STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
ATE472556T1 (de) 2002-12-02 2010-07-15 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
SG11201401562RA (en) 2011-10-18 2014-09-26 Coherus Biosciences Inc Etanercept formulations stabilized with sodium chloride
JP6271536B2 (ja) 2012-07-09 2018-01-31 コヒラス・バイオサイエンシズ・インコーポレイテッド 肉眼不可視粒子の著しい低減を示すエタネルセプト製剤
AU2013315750B9 (en) 2012-09-11 2018-11-15 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
ES3064802T3 (en) 2016-10-21 2026-04-29 Amgen Inc Pharmaceutical formulations and methods of making the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59010908D1 (de) * 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
US7608262B2 (en) * 1996-02-16 2009-10-27 The Kennedy Institute Of Rheumatology Methods of preventing or treating thrombosis with tumor necrosis factor antagonists
AR016551A1 (es) * 1997-07-30 2001-07-25 Smithkline Beecham Corp Derivados de 2-oxindol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos
NL1007890C2 (nl) * 1997-12-24 1999-07-12 Dutch Trading Dutra B V Samenstel van een railsysteem, ten minste één stuk doek en een aantal bevestigingselementen voor bevestiging van het doek aan het railsysteem.
FR2779724B1 (fr) * 1998-06-10 2001-04-20 Rhone Poulenc Rorer Sa Derives du pyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent
CA2366785C (en) * 1999-04-19 2012-02-07 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders

Also Published As

Publication number Publication date
AU2001236764A1 (en) 2001-08-20
MXPA02007683A (es) 2002-12-13
AR033965A1 (es) 2004-01-21
CA2399436A1 (en) 2001-08-16
JP2003522155A (ja) 2003-07-22
EP1261364A1 (en) 2002-12-04
WO2001058473A1 (en) 2001-08-16
CN1406132A (zh) 2003-03-26

Similar Documents

Publication Publication Date Title
BR0213233A (pt) Alcinos inibidores de metaloproteinase de matriz
BR9910029A (pt) Hidróxi indóis, sua aplicação como inibidores da fosfodiesterase 4 e processo para sua preparação
BR9707136A (pt) Derivados morfinóides condesados em heterociclo (ii)
BR0016569A (pt) Processo de isolamento de rna de espécimes de tecido embutidos - parafina fixados - formalina
BR9810706A (pt) Processo para a prevenção ou tratamento do prurido em um mamìfero em necessidade de tal prevenção ou tratamento
BR0308854A (pt) Benzazolas substituìdas e seus usos como inibidoras de quinase raf
BR9810366A (pt) Derivados de ácido 4-bromo ou 4-iodo fenilamino benzidroxîmico e seu uso como inibidores de mek
ATE253062T1 (de) 4- und 5-alkynyloxindole sowie 4- und 5- alkenyloxindole
DK0804437T3 (da) [a]-Annelerede pyrrolderivater og deres anvendelse i farmacien
WO2000009101A3 (en) Use of estrogenic compounds as anti-fungal agents
HUP0103203A2 (hu) Azaadamantánszármazékok és ezeket tartalmazó gyógyszerkészítmények
BR0313729A (pt) Elemento respondente a estrogênio bmp-2 e métodos de uso do mesmo
PT1144365E (pt) Inibidores da adesao de celulas mediada por alfa4beta1
BR9907746A (pt) ácidos 2,3,4,5-tetraidro-1h[1,4]-benzodiazepina-3-hidroxâmic os como inibidores de matriz de metaloproteinase
TR200101756T2 (tr) Protein kinaz inhibitörleri olarak 4,5-pirazinoksindoller.
ATE224372T1 (de) Substituierte 6-alkylphenanthridine
BR9713207A (pt) Derivados de 3-mercaptoacetilamino-1,5-substituìdo-2-oxo-azepan uteis como inibidores de metaloproteinase de matriz
BR0215067A (pt) Piridoquinoxalinas antivirais
BR9910678A (pt) Composto, composição farmacêutica, método para traramento ou prevenção de uma doença inflamatória, método para tratamento de uma condição ou uma doença mediada por mmps, tnf, agrecanase, ou um composto dos mesmos, em um mamìfero, método de redução de nìveis de tnf em pacientes, sem a inibição de mmps, método para tratamento de uma condição ou uma doença e uso de um novo composto
BR0111316A (pt) Xilanase modificada e uso da mesma
BR0307033A (pt) ácidos 3-(imidazolil)-2-aminopropanóicos para o uso como inibidores tafi-a para o tratamento de doenças trombóticas
BG102076A (en) Amorphous coloured plate of crystalizing thermoplast
BR0113461A (pt) Compostos ou sais farmaceuticamente aceitáveis, composições farmacêuticas, método de tratamento de doença ou condição mediada por erab, hadh2 ou (beta)-amilóide em mamìferos, métodos de inibição ou modulação da atividade enzimática de erab ou hadh2 e método de tratamento de mal de alzheimer ou demência em mamìferos
DK1109818T3 (da) Phosphoepoxider, fremgangsmåder til deres fremstilling og deres anvendelser
BRPI0409405A (pt) compostos 7-aza-quinazolina substituìdos

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 6O, 7O E 8O ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2016 DE 25/08/2009